BTK and primary central nervous system lymphoma: With recent data highlighting clinical utility of the Bruton tyrosine kinase inhibitor (BTKi) ibrutinib as monotherapy in salvage treatment of PCNSL, this highlights the value of mapping the genomic landscape of recurrent PCNSL.